Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466855 · ClinicalTrials.gov registry record · Early Phase 1
A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma
A Early Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
NCT01466855 is a Early Phase 1 study that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 36 participants.
The verdict
NCT01466855, a Early Phase 1 study, was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study will test if giving topotecan directly into the blood vessel of the eye will improve the treatment of retinoblastoma. This method is referred to as "selective intra-ophthalmic artery chemotherapy" (SIOAC). The goals of this study are: * To find out if topotecan is an effective treatment for retinoblastoma when delivered directly to the ophthalmic artery (SIOAC delivery) * To find out what kind of effects (good and bad) can be expected when topotecan is given by SIOAC * To assess visual pathway function before and after the study therapy * To learn more about the pharmacology (how your body handles the drug) of topotecan when delivered directly to the ophthalmic artery
Interventions
- DRUG Intra-Ophthalmic Artery Topotecan Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01466855
The ClinicalTrials.gov registry entry for NCT01466855 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intra-Ophthalmic Artery Topotecan Infusion is the first listed.
NCT01466855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01466855 about?
NCT01466855 is a clinical study titled "A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma". This study will test if giving topotecan directly into the blood vessel of the eye will improve the treatment of retinoblastoma. This method is referred to as "selective intra-ophthalmic artery chemotherapy" (SIOAC). The goals of this study are: * To find out if topotecan is an effective treatment...
What is the current status of trial NCT01466855?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2011-10. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01466855?
The interventions under investigation include: Intra-Ophthalmic Artery Topotecan Infusion (DRUG).
Who is sponsoring clinical trial NCT01466855?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.